JPRN-jRCT2031220162SuspendedPhase 2
A Phase 2/3 Study of Evorpacept (ALX148) in Patients With Advanced HER2-overexpressing gastric/gastroesophageal junction adenocarcinoma - ASPEN-06
Fanning Philip0 sites54 target enrollmentStarted: June 25, 2022Last updated:
Conditions
Trial Snapshot
- Phase
- Phase 2
- Status
- Suspended
- Sponsor
- Enrollment
- 54
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Ages
- >= 18age old to ot applicable (—)
- Sex
- All
Inclusion Criteria
- •HER2-overexpressing advanced or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma that has progressed on or after a prior HER2-directed agent and fluoropyrimidine- or platinum-containing chemotherapy (2nd-line or 3rd-line)
- •-Adequate Bone Marrow Function.
- •-Adequate Renal and Liver Function.
- •-Adequate Performance Status.
Exclusion Criteria
- •-Patients with known symptomatic CNS metastases or leptomeningeal disease requiring steroids.
- •-Prior treatment with any anti-CD47 or anti-SIRP alpha agent.
- •-Prior treatment with ramucirumab.
Investigators
Similar Trials
Active, not recruiting
Phase 2
A Study of Evorpacept (ALX148) in Patients With Advanced HER2+ Gastric Cancer (ASPEN-06)Gastroesophageal Junction AdenocarcinomaGastric AdenocarcinomaGastric CancerNCT05002127ALX Oncology Inc.127
Terminated
Phase 1
A Study of Evorpacept (ALX148) With Venetoclax and Azacitidine for Acute Myeloid Leukemia (ASPEN-05)AML, AdultAcute Myeloid LeukemiaNCT04755244ALX Oncology Inc.14
Terminated
Phase 1
A Study of Evorpacept (ALX148) With Azacitidine for Higher Risk Myelodysplastic Syndrome (ASPEN-02)Higher Risk Myelodysplastic SyndromesNCT04417517ALX Oncology Inc.65
Completed
Not Applicable
The effect of Enoxaparin and Aspirin for the prevention of thrombosis after open splenectomyopen splenectomy.Disease of spleen, unspecifiedIRCT2016042527600N1Vice chancellor for research, Ahvaz Jundishapur University of Medical Science126
Active, not recruiting
Phase 1
AUSCorEUCTR2014-002003-25-GBBarts Health NHS Trust54